Heidi S Camp
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.
Fleischmann R, Meerwein S, Charles-Schoeman C, Combe B, Hall S, Khan N, Carter K, Camp H, Rubbert-Roth A. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD Open 2024; 10
25.07.2024Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.
25.07.2024RMD Open 2024; 10
Fleischmann Roy, Meerwein Sebastian, Charles-Schoeman Christina, Combe Bernard, Hall Stephen, Khan Nasser, Carter Kyle M, Camp Heidi S, Rubbert-Roth Andrea
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
Rubbert-Roth A, Kato K, Haraoui B, Rischmueller M, Liu Y, Khan N, Camp H, Xavier R. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study. Rheumatol Ther 2024; 11:1197-1215.
20.07.2024Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
20.07.2024Rheumatol Ther 2024; 11:1197-1215
Rubbert-Roth Andrea, Kato Koji, Haraoui Boulos, Rischmueller Maureen, Liu Yanxi, Khan Nasser, Camp Heidi S, Xavier Ricardo M